Kimia Farma Tbk PT
IDX:KAEF
Kimia Farma Tbk PT
IDX:KAEF
Price:
462
IDR
-0.43%
Market Cap:
Rp2.6T
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Kimia Farma Tbk PT
IDX:KAEF
|
ID |
|
H
|
Hawa Engineers Ltd
BSE:539176
|
IN |
|
C
|
Chromocell Therapeutics Corp
AMEX:CHRO
|
US |
|
G
|
GreenPlus Co Ltd
KOSDAQ:186230
|
KR |
|
Macquarie Korea Infrastructure Fund
KRX:088980
|
KR |
|
Omni Bridgeway Ltd
ASX:OBL
|
AU |
|
DigitalBridge Group Inc
NYSE:DBRG
|
US |
|
Money Forward Inc
OTC:MNYFF
|
JP |
|
L
|
Llorente & Cuenca SA
MAD:LLYC
|
ES |
|
Arbonia AG
SIX:ARBN
|
CH |
|
W
|
WK Kellogg Co
NYSE:KLG
|
US |
|
B
|
BYD Co Ltd
SWB:BY6
|
CN |
|
Mettler-Toledo International Inc
NYSE:MTD
|
US |
|
T
|
Trident Texofab Ltd
BSE:540726
|
IN |
|
G
|
GRC International Group PLC
LSE:GRC
|
UK |
|
Maisons du Monde SA
PAR:MDM
|
FR |
|
E
|
Eureka Acquisition Corp
NASDAQ:EURK
|
CN |
Multiples-Based Value
The Multiples-Based Value of one
KAEF
stock under the Base Case scenario is
hidden
IDR.
Compared to the current market price of 462 IDR,
Kimia Farma Tbk PT
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
KAEF Multiples-Based Value
LOCKED
Multiples Across Competitors
KAEF Competitors Multiples
Kimia Farma Tbk PT Competitors
Kimia Farma Tbk PT Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ID |
|
Kimia Farma Tbk PT
IDX:KAEF
|
2.6T IDR | 0.3 | -4.3 | -15.5 | -15.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
837.7B USD | 12.9 | 40.6 | 27.4 | 29.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
583.9B USD | 6.2 | 21.8 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.4 | 11.5 | 13 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228B GBP | 5.2 | 29.9 | 16.5 | 23.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
292.3B USD | 4.5 | 16 | 9.9 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.6B CHF | 5.3 | 21.3 | 13.2 | 17 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 10 | 7.5 | 8.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.9B USD | 2.5 | 20.3 | 7.8 | 10.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17.1 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
